Genitourinary Cancers (GU)
Clinical Updates
'A Potential Huge Benefit For Patients' - PIVOT-006 and the Future of Intermediate-Risk NMIBC
A Watershed Moment In Bladder Cancer Care, According To Leading Oncologists: The IMvigor011 Study & The Rise Of ctDNA-Guided Treatment
Case Western's Dr. Jorge Garcia On Practical Use of ctDNA To Make Better Treatment Decisions For Bladder Cancer Patients
Intravesical Mitomycin Gel: A New Approach For Recurrent NMIBC
Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer
Should Surgery Be Considered for Oligometastatic Bladder Cancer?
New Combination Of Immunotherapy And Chemotherapy Could Effectively Treat Metastatic Bladder Cancer
The Latest Efforts to Preserve the Bladder
Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management
Withdrawal of Durvalumab for Advanced Bladder Cancer “a Disappointing Loss”
Why Don't Checkpoint Inhibitors Work for More Bladder Cancer Patients?
Perioperative EV + Pembrolizumab For MIBC: The New Standard of Care, According to Leading Bladder Cancer Experts
INLEXZO & SunRISe-1: Enthusiasm and Caution From Two Leading Clinicians
